learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
5 / 801 resultsResearch
5 / 62 resultsresearch Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research The Force Is Strong with This One: Metabolism (Over)powers Stem Cell Fate
Metabolism plays a key role in determining stem cell fate.
research Activation of the integrated stress response in human hair follicles
Blocking the Mitochondrial Pyruvate Carrier causes stress in hair follicles, which can be reduced by an ISR inhibitor.
research The comparison of the mesenchymal progenitor cell coating state on the MBA and DBM as the biochemical scaffolds
The demineralized bone matrix scaffold is better for cell attachment than the mineralized bone allograft.
research Tracing the developmental origin of tissue stem cells
Tissue stem cells originate from specific areas in organs and are vital for organ maintenance and repair.
Community Join
5 / 44 resultscommunity Finally, some real breakthroughs. A comparison of the two leading baldness treatments: PP405 versus ABS-201
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
community Rejux-3x - the copper peptide combo that tressless overlooks.
Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.
community I think we should all keep an eye out for Pelage PP405. February 2025 will be interesting.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community 57% increased chance of pattern hair loss independently associated with the consumption of sugary beverages in men (p<0.001) Pt 2
Sugary beverages increase the risk of pattern hair loss in men by 57%. Treatments discussed include Minoxidil, finasteride, and RU58841.